{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T23:47:44Z","timestamp":1789084064910,"version":"build-2803163510"},"reference-count":75,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T00:00:00Z","timestamp":1673913600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:p>Typically, therapeutic proteins (TPs) have a low risk for eliciting meaningful drug interactions (DIs). However, there are select instances where TP drug interactions (TP\u2010DIs) of clinical concern can occur. This white paper discusses the various types of TP\u2010DIs involving mechanisms such as changes in disease state, target\u2010mediated drug disposition, neonatal Fc receptor (FcRn), or antidrug antibodies formation. The nature of TP drug interaction being investigated should determine whether the examination is conducted as a standalone TP\u2013DI study in healthy participants, in patients, or assessed via population pharmacokinetic analysis. DIs involving antibody\u2013drug conjugates are discussed briefly, but the primary focus here will be DIs involving cytokine modulation. Cytokine modulation can occur directly by certain TPs, or indirectly due to moderate to severe inflammation, infection, or injury. Disease states that have been shown to result in indirect disease\u2013DIs that are clinically meaningful have been listed (i.e., typically a twofold change in the systemic exposure of a coadministered sensitive cytochrome P450 substrate drug). Type of disease and severity of inflammation should be the primary drivers for risk assessment for disease\u2013DIs. While more clinical inflammatory marker data needs to be collected, the use of two or more clinical inflammatory markers (such as C\u2010reactive protein, albumin, or interleukin 6) may help broadly categorize whether the predicted magnitude of inflammatory disease\u2013DI risk is negligible, weak, or moderate to strong. Based on current knowledge, clinical DI studies are not necessary for all TPs, and should no longer be conducted in certain disease patient populations such as psoriasis, which do not have sufficient systemic inflammation to cause a meaningful indirect disease\u2013DI.<\/jats:p>","DOI":"10.1002\/cpt.2814","type":"journal-article","created":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T14:09:53Z","timestamp":1670508593000},"page":"1185-1198","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Therapeutic Protein Drug Interactions: A White Paper From the International Consortium for Innovation and Quality in Pharmaceutical Development"],"prefix":"10.1111","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6291-5623","authenticated-orcid":false,"given":"David E.","family":"Coutant","sequence":"first","affiliation":[{"name":"Drug Disposition Department Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Boulton","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Quantitative Pharmacology Clinical Pharmacology and Safety Sciences, Research &amp; Development, AstraZeneca  Gaithersburg Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Upendra P.","family":"Dahal","sequence":"additional","affiliation":[{"name":"Pharmacokinetics and Drug Metabolism Amgen, Inc.  South San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Deslandes","sequence":"additional","affiliation":[{"name":"Translational Medicine and Early Development Sanofi Research &amp; Development  Chilly\u2010Mazarin France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Grimaldi","sequence":"additional","affiliation":[{"name":"Formerly of Drug Metabolism and Pharmacokinetics Boehringer Ingelheim Pharmaceuticals, Inc  Ridgefield Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joao N.S.","family":"Pereira","sequence":"additional","affiliation":[{"name":"Drug Disposition &amp; Design Merck Healthcare KGaA  Darmstadt Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"S\u00e4ll","sequence":"additional","affiliation":[{"name":"Development Absorption, Distribution, Metabolism, and Elimination Novo Nordisk A\/S  M\u00e5l\u00f8v Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hetal","family":"Sarvaiya","sequence":"additional","affiliation":[{"name":"Drug Metabolism, Pharmacokinetics, and Bioanalytical, AbbVie Inc.  California South San Francisco USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1026-3985","authenticated-orcid":false,"given":"Hilmar","family":"Schiller","sequence":"additional","affiliation":[{"name":"Pharmacokinetic Sciences Novartis Institutes for BioMedical Research  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoying","family":"Tai","sequence":"additional","affiliation":[{"name":"Department of Metabolism and Pharmacokinetics GlaxoSmithKline  Collegeville Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Umehara","sequence":"additional","affiliation":[{"name":"Pharmaceutical Sciences Roche Pharma Research &amp; Early Development, Roche Innovation Center Basel  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yuan","sequence":"additional","affiliation":[{"name":"Formerly of Department of Metabolism and Pharmacokinetics Bristol Myers Squibb Pharmaceutical Research and Development  Princeton New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Dallas","sequence":"additional","affiliation":[{"name":"Preclinical Sciences &amp; Translational Safety Janssen Research &amp; Development  Springhouse Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,1,17]]},"reference":[{"key":"e_1_2_11_1_1","unstructured":"US Food and Drug Administration.Draft guidance: drug\u2013drug interaction assessment for therapeutic proteins. <https:\/\/www.fda.gov\/media\/140909\/download> (2020). Accessed February 10 2022."},{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.35"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1058"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1558"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12936"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0730-x"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13670"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0462-8"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12807"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.561"},{"key":"e_1_2_11_11_1","unstructured":"ClinicalTrials.gov. A Phase 4 Vedolizumab\u20104002 Post\u2010Marketing Disease\u2010Drug\u2010Drug Interaction Study.Postmarket Requirements and Commitments. Vedolizumab. <https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02760615?intr=vedolizumab&phase=3&draw=3&rank=20> (2022). Accessed January 2 2023."},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.33"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/10600280211022281"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2014.143"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-820018-6.00013-2"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-802949-7.00002-X"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1093"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-199611000-00009"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.04019.x"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.69.4.476"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-009-0777-6"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13259"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1994.82"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-003-1758-3"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-008-1358-3"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2000.00314.x"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000001062"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-020-00933-8"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12808"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.115.065979"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.8b00159"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2013.12.010"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.128"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12730"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01177-20"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa195"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1115"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2432"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1210\/endo.139.5.6001"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00810-z"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(98)00372-4"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13097"},{"key":"e_1_2_11_43_1","unstructured":"US Food and Drug Administration.SILIQ\u2122 (brodalumab) Label<https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761032lbl.pdf> (2017). Accessed August 2 2022."},{"key":"e_1_2_11_44_1","unstructured":"US Food and Drug Administration.TALTZ (ixekizumab) Label<https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/125521s024lbl.pdf> (2022). Accessed August 2 2022."},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.3390\/antib9020024"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aax9586"},{"key":"e_1_2_11_47_1","unstructured":"US Food and Drug Administration.VYVGART\u2122 (efgartigimod alfa\u2010fcab) Label. <https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761195s000lbl.pdf> (2021). Accessed August 2 2022."},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1Q583"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S195113"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00312"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001047"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-018-0219-4"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-017-3242-8"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2448"},{"key":"e_1_2_11_55_1","first-page":"1","article-title":"The resurgence of antibody drug conjugates in cancer therapeutics: novel targets and payloads","volume":"40","author":"Boni V.","year":"2020","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"e_1_2_11_56_1","first-page":"73","volume-title":"Drug\u2013Drug Interactions for Therapeutic Biologics","author":"Nguyen T.","year":"2013"},{"key":"e_1_2_11_57_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.113.052225"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1496"},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.110.034223"},{"key":"e_1_2_11_60_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.23570"},{"key":"e_1_2_11_61_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.539"},{"key":"e_1_2_11_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2013.79"},{"key":"e_1_2_11_63_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-019-0309-y"},{"key":"e_1_2_11_64_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-016-9890-5"},{"key":"e_1_2_11_65_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12003"},{"key":"e_1_2_11_66_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-021-03019-7"},{"key":"e_1_2_11_67_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2402"},{"key":"e_1_2_11_68_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12447"},{"key":"e_1_2_11_69_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12938"},{"key":"e_1_2_11_70_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.921"},{"key":"e_1_2_11_71_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-016-9464-2"},{"key":"e_1_2_11_72_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.240"},{"key":"e_1_2_11_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2011.03.028"},{"key":"e_1_2_11_74_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.086561"},{"key":"e_1_2_11_75_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13793"}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.2814","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpt.2814","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.2814","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T13:31:50Z","timestamp":1699363910000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.2814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,17]]},"references-count":75,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1002\/cpt.2814"],"URL":"https:\/\/doi.org\/10.1002\/cpt.2814","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,17]]},"assertion":[{"value":"2022-08-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}